{"title":"Association between time-varying weighted hemoglobin and all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock.","authors":"Xia Liu, Tianbo Gong, Yongpeng Zhang","doi":"10.3389/fcvm.2025.1516100","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Anemia has been implicated in prognosis across ischemic heart diseases. This study aimed to investigate the association between time-weighted average hemoglobin (TWA-Hb) and all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS).</p><p><strong>Methods and results: </strong>We conducted a retrospective analysis of 765 patients diagnosed with AMI-CS using data from the MIMIC-IV database (2008-2019). Kaplan-Meier survival analysis demonstrated that lower TWA-Hb levels were associated with higher cumulative mortality rates at 28 days, 90 days, 6 months, and 1 year (log-rank <i>P</i> = 0.002, 0.006, 0.048, and 0.005, respectively). Landmark analyses further revealed a sustained increase in mortality risk associated with lower TWA-Hb during the 28-day to 1-year follow-up period. Multivariable Cox regression analysis identified low TWA-Hb as an independent predictor of mortality risk at 90 days (<i>P</i> = 0.026), 6 months (<i>P</i> = 0.023), and 1 year (<i>P</i> = 0.021). Each one-unit increase in TWA-Hb was associated with a 0.93-, 0.76- and 0.71-fold decrease in the risk of 90-day, 6-month, and 1-year mortality, correspondingly. Subgroup analyses stratified by age, BMI, and comorbidities consistently supported these findings (all <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Low TWA-Hb is associated with long-term mortality in patients with AMI-CS. These findings imply that the application of this indicator in clinical practice could improve long-term risk stratification.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1516100"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116649/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1516100","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: Anemia has been implicated in prognosis across ischemic heart diseases. This study aimed to investigate the association between time-weighted average hemoglobin (TWA-Hb) and all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS).
Methods and results: We conducted a retrospective analysis of 765 patients diagnosed with AMI-CS using data from the MIMIC-IV database (2008-2019). Kaplan-Meier survival analysis demonstrated that lower TWA-Hb levels were associated with higher cumulative mortality rates at 28 days, 90 days, 6 months, and 1 year (log-rank P = 0.002, 0.006, 0.048, and 0.005, respectively). Landmark analyses further revealed a sustained increase in mortality risk associated with lower TWA-Hb during the 28-day to 1-year follow-up period. Multivariable Cox regression analysis identified low TWA-Hb as an independent predictor of mortality risk at 90 days (P = 0.026), 6 months (P = 0.023), and 1 year (P = 0.021). Each one-unit increase in TWA-Hb was associated with a 0.93-, 0.76- and 0.71-fold decrease in the risk of 90-day, 6-month, and 1-year mortality, correspondingly. Subgroup analyses stratified by age, BMI, and comorbidities consistently supported these findings (all P < 0.05).
Conclusion: Low TWA-Hb is associated with long-term mortality in patients with AMI-CS. These findings imply that the application of this indicator in clinical practice could improve long-term risk stratification.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.